Skip to main content
SpringerLink
Log in
Book cover

Cancer Therapeutic Targets pp 1–9Cite as

BH3-Only Mimetics

  • Living reference work entry
  • First Online:

  • 185 Accesses

Abstract

BH3 mimetics are a class of drugs designed to tip the balance of pro- and anti-apoptotic factors within a cell to favor apoptosis. They bind within a specific groove of anti-apoptotic Bcl-2 family survival factors in a similar manner to native proteins within the cell that regulate these factors. This primes the cell for apoptosis. Several small molecule BH3 mimetics are currently undergoing evaluation in clinical trials.

This is a preview of subscription content, log in via an institution.

References

  • Cartron PF, Loussouarn D, Campone M, Martin SA, Vallette FM. Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis. 2012;3:e421.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17:393–403.

    Article  CAS  PubMed  Google Scholar 

  • Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ, Subramaniam DS, Schnyder J, et al. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer. 2012;106:839–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer. 2009;9:321–6.

    Article  CAS  PubMed  Google Scholar 

  • Craik AC, Veldhoen RA, Czernick M, Buckland TW, Kyselytzia K, Ghosh S, Lai R, Damaraju S, Underhill DA, Mackey JR, et al. The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism. Oncogene. 2010;29:5381–91.

    Article  CAS  PubMed  Google Scholar 

  • Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3127–35.

    Article  CAS  Google Scholar 

  • DeVita VT, Lawrence TS, Rosenberg SA. Cancer: principles & practice of oncology: primer of the molecular biology of cancer. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.

    Google Scholar 

  • Elkholi R, Floros KV, Chipuk JE. The role of BH3-only proteins in tumor cell development, signaling, and treatment. Genes Cancer. 2011;2:523–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. J Cell Sci. 2012;125:1081–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hartman ML, Czyz M. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy. Anti Cancer Agents Med Chem. 2012;12:966–81.

    Article  CAS  Google Scholar 

  • Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, et al. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2010;5:1637–43.

    Google Scholar 

  • Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT, Yeoh AE. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol. 2011;39:321–9. 329 e321-323.

    Article  CAS  PubMed  Google Scholar 

  • Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 2011;18:1414–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Khosravi-Far R, White E. Programmed cell death in cancer progression and therapy. Berlin: Springer; 2008.

    Book  Google Scholar 

  • Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.

    Article  CAS  PubMed  Google Scholar 

  • Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:3172–6.

    Article  CAS  Google Scholar 

  • Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene. 2008;27 Suppl 1:S2–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113:299–305.

    Article  PubMed  Google Scholar 

  • Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012;119:2171–2.

    Article  CAS  PubMed  Google Scholar 

  • Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011;74:481–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:488–96.

    Article  CAS  Google Scholar 

  • Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:3163–9.

    Article  CAS  Google Scholar 

  • Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2008a;14:4128–33.

    Article  CAS  Google Scholar 

  • Sinicrope FA, Rego RL, Okumura K, Foster NR, O’Connell MJ, Sargent DJ, Windschitl HE. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2008b;14:5810–8.

    Article  CAS  Google Scholar 

  • Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.

    Article  CAS  PubMed  Google Scholar 

  • Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305:1466–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institutes of Health, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 5116B, Bethesda, MD, 20892, USA

    Christine Alewine

Authors
  1. Christine Alewine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Alewine .

Editor information

Editors and Affiliations

  1. Georgetown University Div. Hematology & Oncology, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science Business Media, New York (outside the USA)

About this entry

Cite this entry

Alewine, C. (2014). BH3-Only Mimetics. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_65-4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6613-0_65-4

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6613-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation